Inclusion Criteria:

- Histologically or cytologically documented, incurable, or metastatic solid malignancy
that has progressed on, or failed to respond to regimens or therapies known to
provide clinical benefit

Exclusion Criteria:

- Inadequate hematologic and organ function

- Anti-cancer therapy within 4 weeks prior to initiation of study treatment

- Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1,
except for alopecia

- Active infection or autoimmune disease

- Pregnancy (positive pregnancy test) or lactation